KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Net Cash Flow: 2018-2025

Historic Net Cash Flow for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -$148.0 million.

  • Moderna's Net Cash Flow rose 82.25% to -$148.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$514.0 million, marking a year-over-year increase of 60.67%. This contributed to the annual value of -$999.0 million for FY2024, which is 245.67% down from last year.
  • According to the latest figures from Q3 2025, Moderna's Net Cash Flow is -$148.0 million, which was up 57.23% from -$346.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Net Cash Flow ranged from a high of $2.8 billion in Q1 2021 and a low of -$2.2 billion during Q2 2022.
  • For the 3-year period, Moderna's Net Cash Flow averaged around -$189.5 million, with its median value being -$148.0 million (2025).
  • In the last 5 years, Moderna's Net Cash Flow surged by 1,705.77% in 2021 and then slumped by 1,450.93% in 2022.
  • Over the past 5 years, Moderna's Net Cash Flow (Quarterly) stood at $1.3 billion in 2021, then tumbled by 86.45% to $176.0 million in 2022, then tumbled by 114.20% to -$25.0 million in 2023, then spiked by 1,232.00% to $283.0 million in 2024, then spiked by 82.25% to -$148.0 million in 2025.
  • Its Net Cash Flow stands at -$148.0 million for Q3 2025, versus -$346.0 million for Q2 2025 and -$303.0 million for Q1 2025.